Isobutyryl-L-cysteine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Isobutyryl-L-cysteine
• 英文别名: 2-(2-methylpropanoylamino)-3-sulfanylpropanoic acid
• 化学式: C₇H₁₃NO₃S
• 分子量: 191.25
• InChiKey: BWBQXMAXLAHHTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  67.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Methylphenidate-Prodrugs, Processes of Making and Using the Same
  申请人：KemPharm, Inc.

  公开号：US20150266911A1

  公开（公告）日：2015-09-24

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  目前的技术是针对前药和组合物的，用于治疗包括甲基苯丙胺或甲基苯丙胺衍生物的至少与醇、胺、羧酸、硫醇或其衍生物结合的各种疾病和/或紊乱。在某些实施例中，这些结合物还包括至少一个连接剂。该技术还涉及合成甲基苯丙胺或甲基苯丙胺衍生物，结合至少一个醇、胺、羧酸、硫醇或其衍生物或其组合的方法。
• D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAME
  申请人：KemPharm, Inc.

  公开号：US20200131130A1

  公开（公告）日：2020-04-30

  Disclosed are d-amphetamine compounds and compositions comprising at least one organic acid covalently bound to d-amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.

  揭示了d-安非他明化合物和组合物，其中至少有一种有机酸以共价键结合到d-安非他明，其盐，衍生物或其组合物。还公开了制备和使用这些化合物的方法。
• [EN] HYDROXYNORKETAMINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS D'HYDROXYNORKÉTAMINE POUR LE TRAITEMENT DES TROUBLES DU SNC
  申请人：DART NEUROSCIENCE LLC

  公开号：WO2018044896A1

  公开（公告）日：2018-03-08

  Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

  化学实体的化学式（I）：包括其对映体，其中R1具有本文描述的任何值，并包括这些化学实体的组合物；它们的制备；以及它们在各种方法中的使用，包括治疗抑郁症、疼痛、认知障碍、神经退行性疾病和其他神经系统和外周疾病。
• COMPOUNDS FOR THERAPEUTIC USE
  申请人：Dart NeuroScience, LLC

  公开号：US20180057470A1

  公开（公告）日：2018-03-01

  Chemical entities of Formula (I): Including enantiomers thereof, wherein R 1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

  化学实体的化学式（I）：包括其对映体，其中R1具有本文描述的任何值，并包含这些化学实体的组合物；它们的制备；以及它们在各种方法中的使用，包括治疗抑郁症、疼痛、认知障碍、神经退行性疾病和其他神经系统和外周疾病。
• [EN] LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM<br/>[FR] PROMÉDICAMENTS DE LÉVORPHANOL ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：KEMPHARM INC

  公开号：WO2018191474A1

  公开（公告）日：2018-10-18

  The presently described technology provides compositions of one or more of oxoacids, amino acids, polyethylene glycols, and/or vitamin compounds chemically conjugated to levorphanol ((-)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol.

  目前描述的技术提供了由羟酸、氨基酸、聚乙二醇和/或维生素化学共轭到左氧吗啉((-)-17-甲基吗啉-3-醇)的一个或多个组合物，形成新型的前药和左氧吗啉的组合物。